A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
Phase 4
30,000
about 1.6 years
50–64
150 sites in AL, AZ, CA +35
About this study
Researchers are testing a treatment, mRNA-1273 and mRNA-1283, in adults aged 50 to 64 who do not have high risk factors for severe COVID-19. The trial will last about 567 days and aims to see if the treatments are effective and safe.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Placebo
- 2.Receive mRNA-1273
- 3.Receive mRNA-1283
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of Participants with Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs of Special Interest (AESIs), and AEs Leading to Discontinuation, Number of Participants with Unsolicited Adverse Events (AEs)
Infectious